896 related articles for article (PubMed ID: 24788977)
1. Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion.
Braithwaite T; Nanji AA; Lindsley K; Greenberg PB
Cochrane Database Syst Rev; 2014 May; 2014(5):CD007325. PubMed ID: 24788977
[TBL] [Abstract][Full Text] [Related]
2. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Mitry D; Bunce C; Charteris D
Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
[TBL] [Abstract][Full Text] [Related]
3. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Shalchi Z; Mahroo O; Bunce C; Mitry D
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD009510. PubMed ID: 32633861
[TBL] [Abstract][Full Text] [Related]
4. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD005139. PubMed ID: 30834517
[TBL] [Abstract][Full Text] [Related]
5. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
Cochrane Database Syst Rev; 2014 Aug; 8(8):CD005139. PubMed ID: 25170575
[TBL] [Abstract][Full Text] [Related]
6. Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion.
Braithwaite T; Nanji AA; Greenberg PB
Cochrane Database Syst Rev; 2010 Oct; (10):CD007325. PubMed ID: 20927757
[TBL] [Abstract][Full Text] [Related]
7. Anti-vascular endothelial growth factor for diabetic macular oedema.
Virgili G; Parravano M; Menchini F; Evans JR
Cochrane Database Syst Rev; 2014 Oct; (10):CD007419. PubMed ID: 25342124
[TBL] [Abstract][Full Text] [Related]
8. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
Virgili G; Parravano M; Evans JR; Gordon I; Lucenteforte E
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007419. PubMed ID: 28639415
[TBL] [Abstract][Full Text] [Related]
9. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
Virgili G; Parravano M; Evans JR; Gordon I; Lucenteforte E
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD007419. PubMed ID: 30325017
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema.
Virgili G; Parravano M; Menchini F; Brunetti M
Cochrane Database Syst Rev; 2012 Dec; 12():CD007419. PubMed ID: 23235642
[TBL] [Abstract][Full Text] [Related]
11. Aflibercept for neovascular age-related macular degeneration.
Sarwar S; Clearfield E; Soliman MK; Sadiq MA; Baldwin AJ; Hanout M; Agarwal A; Sepah YJ; Do DV; Nguyen QD
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD011346. PubMed ID: 26857947
[TBL] [Abstract][Full Text] [Related]
12. Macular grid laser photocoagulation for branch retinal vein occlusion.
Lam FC; Chia SN; Lee RM
Cochrane Database Syst Rev; 2015 May; 2015(5):CD008732. PubMed ID: 25961835
[TBL] [Abstract][Full Text] [Related]
13. Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.
Mehta H; Hennings C; Gillies MC; Nguyen V; Campain A; Fraser-Bell S
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011599. PubMed ID: 29669176
[TBL] [Abstract][Full Text] [Related]
14. Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia.
Zhu Y; Zhang T; Xu G; Peng L
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD011160. PubMed ID: 27977064
[TBL] [Abstract][Full Text] [Related]
15. Anti-vascular endothelial growth factor for proliferative diabetic retinopathy.
Martinez-Zapata MJ; Martí-Carvajal AJ; Solà I; Pijoán JI; Buil-Calvo JA; Cordero JA; Evans JR
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD008721. PubMed ID: 25418485
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.
Hykin P; Prevost AT; Sivaprasad S; Vasconcelos JC; Murphy C; Kelly J; Ramu J; Alshreef A; Flight L; Pennington R; Hounsome B; Lever E; Metry A; Poku E; Yang Y; Harding SP; Lotery A; Chakravarthy U; Brazier J
Health Technol Assess; 2021 Jun; 25(38):1-196. PubMed ID: 34132192
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion.
Gewaily D; Muthuswamy K; Greenberg PB
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD007324. PubMed ID: 26352007
[TBL] [Abstract][Full Text] [Related]
18. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
Virgili G; Curran K; Lucenteforte E; Peto T; Parravano M
Cochrane Database Syst Rev; 2023 Jun; 2023(6):CD007419. PubMed ID: 38275741
[TBL] [Abstract][Full Text] [Related]
19. Anti-vascular endothelial growth factor biosimilars for neovascular age-related macular degeneration.
Sunaga T; Maeda M; Saulle R; Ng SM; Sato MT; Hasegawa T; Mason AN; Noma H; Ota E
Cochrane Database Syst Rev; 2024 Jun; 6(6):CD015804. PubMed ID: 38829176
[TBL] [Abstract][Full Text] [Related]
20. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy.
Smith JM; Steel DH
Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD008214. PubMed ID: 26250103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]